Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010910 | 0.89 | CYP2C19 (0.40) | CYP2C19POLBMAPTHTTNPSR1 | |
| SCHEMBL31033301 | 0.82 | POLB (0.33) | CYP2C19POLBMAPTHTTGAA | |
| SCHEMBL31033322 | 0.81 | HSD17B10 (0.39) | POLBHTTALDH1A1GAAMEN1 | |
| SCHEMBL22010745 | 0.81 | HSD17B10 (0.39) | POLBHTTALDH1A1GAAMEN1 | |
| SCHEMBL22010482 | 0.79 | GLA (0.35) | CYP2C19POLBMAPTHTTNPSR1 | |
| SCHEMBL31033297 | 0.79 | GLA (0.35) | CYP2C19POLBMAPTHTTNPSR1 | |
| SCHEMBL28612741 | 0.79 | MAPT (0.36) | CYP2C19POLBMAPTNPSR1ALDH1A1 | |
| SCHEMBL21963967 | 0.79 | GAA (0.33) | CYP2C19POLBMAPTHTTALDH1A1 | |
| SCHEMBL31497985 | 0.78 | MAPT (0.35) | POLBMAPTALDH1A1GAAKMT2A | |
| SCHEMBL31497995 | 0.78 | GLA (0.40) | POLBMAPTHTTRECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| EP-3880675-B1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INT SA (CH) | 2024-11-06 | — | — | EP | disclosed |
| CN-113272302-B | Antibiotic compound, method for producing same, pharmaceutical composition containing same, and use thereof | 德彪药业国际股份公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| EP-3880675-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | Debiopharm International SA (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113272302-A | Antibiotic compounds, process for their manufacture, pharmaceutical compositions containing them and their use | 德彪药业国际股份公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | CYP2C19 204/4885POLB 1420/4885MAPT 4422/4885 |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | CYP2C19 98/4885POLB 629/4885MAPT 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.